NF-AT derived polypeptides that bind calcineurin and uses...

Details NF-AT derived polypeptides that bind calcineurin and uses... NF-AT derived polypeptides that bind calcineurin and uses...

2000-04-14

2004-08-24

Wax, Robert A. (Department: 1653)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

C435S004000, C530S350000

Reexamination Certificate

active

06780597

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to novel polynucleotides, polypeptides encoded by them, use of the polynucleotides and polypeptides, and a method for producing them. More particularly, the present invention relates to Calcineurin (CN)-binding polypeptides.
BACKGROUND OF THE INVENTION
The calcium/calmodulin-dependent serine/threonine phosphatase, Calcineurin (CN) (Masuda, E. S. et al., 1999, Cell. Signaling 10:599), is a heterodimeric protein composed of a calmodulin-binding catalytic subunit, CNA, and a Ca
2+
-binding regulatory subunit, CNB (Kincaid, R. 1993, Adv. Second Messenger Phosphoprotein Res. 27:1). CN is a target of the immunosuppressive drugs cyclosporin A (CSA) and FK506, which block T cell function by preventing transcriptional activation of cytokine genes. It has been suggested that CN plays an essential role in calcium-dependent dephosphorylation signal transduction pathways and subsequently leads to production of cytokines in T cells (Crabtree, G. R., and N. A. Clipstone, 1994, Annu. Rev. Biochem. 63:1045). Further studies have revealed that the potential of CN to regulate the expression of cytokine genes is largely due to effects on activation of a transcription factor termed nuclear factor of activated T cells (NF-AT) (Rao, A. et al., 1997, Annu. Rev. Immunol. 15:707; Masuda, E. S. et al., 1999, Cell. Signaling 10:599).
Currently, five NF-AT family members (NF-AT1/NF-ATp, NF-ATc/NF-AT2, NF-ATx/NF-AT4/NF-ATc3, NF-AT3, and TonE-BP/NF-AT5) have been identified, and they share functional and structural similarities (Hoey, T. et al., 1995, Immunity 2:461; Masuda, E. S. et al., 1995, Mol. Cell. Biol. 15:2697; McCaffrey, P. G. et al., 1993, Science 262:750; Northrop, J. P. et al., 1994, Nature 369:497; Miyakawa, H. et al., 1999, Proc. Natl. Acad. Sci. USA 96: 2538-42; Lopez-Rodriguez, C. et al., 1999, Proc. Natl. Acad. Sci. USA 96: 7214-9). The NF-AT complex is composed of at least two components. Both activation of the protein kinase C/Ras pathway and the elevated level of intracellular calcium are required for activation of this complex. The former is responsible for formation of the AP1 (activating protein-1) complex, as the nuclear components of NF-AT, while the latter leads to translocation of NF-AT from the cytoplasm to the nucleus, where it binds with AP1 at IL-2 promoter NF-AT sites (Crabtree, G. R., and N. A. Clipstone, 1994, Annu. Rev. Biochem. 63:1045; Rao, A. 1994, Immunol. Today 15:274). Thus, nuclear transport is a critical step that allows NF-AT to function in the nucleus. CN has been shown to dephosphorylate NF-AT, the result being nuclear translocation of NF-AT (Karen, T.-Y. S. et al., 1995,
Natl. Acad. Sci. USA 92:11205), which can be inhibited by and FK506 (Bierer, B. E. 1994, Chem. Immunol. 59:128).
NF-AT protein is functionally divided into three domains. First, the Rel similarity domain (RSD) has a high sequence homology among different family members. It is responsible for DNA binding and cooperatively interacts with AP1 proteins (Hoey, T. et al., 1995, Immunity 2:461; McCaffrey, P. G. et al., 1993, Science 262:750; Jain, J. et al., 1995, J. Biol. Chem. 270:4138). In addition, one of the two putative conserved nuclear localization signals (NLSs) present in NF-AT family members is located within RSD (Hoey, T. et al., 1995, Immunity 2:461; Masuda, E. S. et al., 1995, Mol. Cell. Biol. 15:2697; McCaffrey, P. G. et al., 1993, Science 262:750; Northrop, J. P. et al., 1994, Nature 369:497). Second, a C-terminal domain eliciting less sequence homology has been reported to bear a transactivation motif (Imamura, R. et al., 1998, J. Immunol. 161:3455). The third domain showing homology among NF-AT proteins is the N-terminal domain. Several conserved motifs, such as SP boxes that are rich in serines and prolines (Masuda, E. S. et al., 1995, Mol. Cell. Biol. 15:2697), CN-regulated inhibitory (CRI) sequence/serine-rich region (SRR) (Masuda, E. S. et al., 1997, Mol. Cell. Biol. 17:2066; Beals, C. R. et al., 1997, Genes Dev. 11:824), and another functional NLS (Beals, C. R. et al., 1997, Genes Dev. 11:824; Luo, C. et al., 1996, Proc. Natl. Acad. Sci. USA 93:8907), have been identified within the N-terminal domain. The conserved serine residues in the SRR motif were found to be constitutively phosphorylated by cellular kinases and can be dephosphorylated by CN (Beals, C. R. et al., 1997, Genes Dev. 11:824). Deletion of CRI in human NF-ATx1 (hNF-ATx1) or mutation of serines in the SRR motif of NF-ATc led to the constitutive nuclear translocation of either hNF-ATx1or NF-ATc (Masuda, E. S. et al., 1997, Mol. Cell. Biol. 17:2066; Beals, C. R. et al., 1997, Genes Dev. 11:824). Furthermore, at least two conserved NLSs have been reported to be essential for the nuclear translocation of NF-ATc; one NLS located in RSD is associated with the majority of phosphorylated serines in SRR (Beals, C. R. et al., 1997, Genes Dev. 11:824). Thus, NLS is probably masked by these phosphorylated serine residues. Both the domain interacting with CN and residues dephosphorylated by CN have been mapped within the N-terminus of NF-AT (Masuda, E. S. et al., 1995, Mol. Cell. Biol. 15:2697; Beals, C. R. et al., 1997, Genes Dev. 11:824; Luo, C. et al., 1996, Proc. Natl. Acad. Sci. USA 93:8907), suggesting that the N-terminal domain of NF-AT is a target of CN action involved in major activities of the Ca
2+
signaling pathway and is important for the nuclear localization of NF-AT. However, detailed interaction between CN and NF-AT has not been clarified.
SUMMARY OF THE INVENTION
Structural and functional analyses of the N-terminal domain of murine NF-ATx1 (mNF-ATx1), (Liu, J. et al., 1997, Mol. Biol. Cell. 8:157), a member of the NF-AT family, have defined two distinct CN binding regions (CNBRs), CNBR1 and CNBR2, which are located in the region preceding the SP boxes of serine/proline-rich sequences and the region between the SP boxes and Rel similarity domain, respectively. Each of the two CN binding regions has the capacity to independently bind CN. The binding of mNF-ATx1 to CN was abolished by deletion of these two regions, yet was unaffected by the individual deletion. In contrast, the nuclear translocation of mNF-ATx1 was much reduced when only CNBR2 was removed. Luciferase assay revealed that both regions are required for mNF-ATx1-dependent activation of the murine IL-2 promoter. Most importantly, recombinant CNBR2 bound CN with a higher affinity, and when expressed in Jurkat cells, it functioned as a dominant negative mutant that prevented the transcription driven by exogenous mNF-ATx1, probably by interfering with the function of CN. The present invention revealed important features of the interaction of mNF-ATx1 with CN via the CN binding region, and light was shed on a structure-function model of mNF-ATx1 proteins. The finding that one of two CN binding regions acts as an inhibitor of mNF-ATx1 opens the way for development of immunosuppressive agents. The present invention provides a new opportunity for pharmacological intervention with Ca
2+
-dependent signaling events.
In one aspect, the invention relates to CN binding polypeptides and DNAs encoding them, and methods for their production.
Another aspect of the invention relates to methods for using polypeptides and polynucleotides of the invention. In particular, the present invention relates to a method for screening a compound that inhibits interation between NF-AT and CN using the polypeptides of the present invention.
Still another aspect of the present invention is pharmaceutical compositions comprising a polypeptide of the present invention or a compound isolable by the above screening method. The pharmaceutical compositions can be used to inhibit interaction between NF-AT and CN. CN/NF-AT signal transduction is involved in induction of an immune response. Immunoreaction can thus be suppressed by inhibiting interaction between NF-AT and CN. The pharmaceutical compositions of this invention are especially useful for suppressing rejection after transplantation of organs and treating or preventing

Affiliated with

Also associated with

Rating

NF-AT derived polypeptides that bind calcineurin and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with NF-AT derived polypeptides that bind calcineurin and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and NF-AT derived polypeptides that bind calcineurin and uses... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3359538